Brief: Kodiak Sciences Announces Topline Results From Its Phase 3 Studies Of Tarcocimab Tedromer In Neovascular Age-Related Macular Degeneration And Diabetic Macular Edema

Kodiak Sciences

24/07/2023 11:07

July 24 (Reuters) - Kodiak Sciences Inc  KOD.O :
    * KODIAK SCIENCES ANNOUNCES TOPLINE RESULTS FROM ITS PHASE 3
STUDIES OF TARCOCIMAB TEDROMER IN NEOVASCULAR AGE-RELATED
MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA AND PROVIDES
UPDATE ON TARCOCIMAB DEVELOPMENT PROGRAM
    * KODIAK SCIENCES INC - DAYLIGHT STUDY MET PRIMARY ENDPOINT
    * KODIAK SCIENCES INC - TARCOCIMAB WAS SAFE AND WELL
TOLERATED IN
STUDY AND WITH A LOW RATE OF INTRAOCULAR INFLAMMATION
    * KODIAK SCIENCES INC - KODIAK HAS MADE A BUSINESS DECISION
TO
DISCONTINUE FURTHER DEVELOPMENT OF TARCOCIMAB
    * KODIAK SCIENCES INC - GLEAM AND GLIMMER STUDIES DID NOT
MEET
THEIR PRIMARY EFFICACY ENDPOINTS
    * KODIAK SCIENCES INC - REMAINS WELL FINANCED WITH ABOUT
$379
MILLION CASH AND CASH EQUIVALENTS AS OF JUNE 30
    * KODIAK SCIENCES INC - UNEXPECTED INCREASE IN CATARACTS WAS
OBSERVED OVER TIME IN TARCOCIMAB ARMS OF BOTH GLEAM AND GLIMMER
    * KODIAK SCIENCES: ASSESSING WHETHER TO CONTINUE DEVELOPMENT
OF
KSI-501 BOTH AS UNCONJUGATED PROTEIN AND ITS BIOCONJUGATE FORM

Source text for Eikon:  ID:nPn9zm5sma 
Further company coverage:  KOD.O 

 ((Reuters.Briefs@thomsonreuters.com;))